{"url_path":"/sec/adct/8-k/2026-06-03/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/0000950103-26-008465-index.html","accession_number":"0000950103-26-008465","cik":"0001771910","ticker":"ADCT","issuer_name":"ADC Therapeutics SA","edgar_url":"https://www.sec.gov/Archives/edgar/data/1771910/0000950103-26-008465-index.html","primary_entity_key":"0001771910","primary_entity_name":"ADC Therapeutics SA"},"word_count":313,"has_tables":true,"body_markdown":"false\n0001771910\n\n0001771910\n\n2026-06-03\n2026-06-03\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934**\n\nDate of Report (Date\nof Earliest Event Reported): June 3, 2026\n\n \n\n**ADC Therapeutics SA**\n\n(Exact Name of Registrant as Specified in Its Charter)\n\n  \n\n**Switzerland**\n\n(State or Other Jurisdiction of Incorporation)\n\n**001-39071**\n\n(Commission File Number)\n\n**N/A**\n\n(IRS Employer Identification Number)\n\n \n\n**Biopôle**\n\n**Route de la Corniche 3B**\n\n**1066 Epalinges**\n\n**Switzerland**\n\n(Address of Principal Executive Offices) (Zip Code)\n\n**+41 21 653 02 00**\n\n(Registrant’s Telephone Number)\n\n  \n\n**N/A** \n\n(Former Name or Former Address, if Changed Since\nLast Report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.\nbelow):\n\n \n\n☐Written communications pursuant to Rule 425 under the Securities\nAct (17 CFR 230.425)\n\n \n\n☐Soliciting material pursuant to Rule 14a-12 under the Exchange\nAct (17 CFR 240.14a-12)\n\n \n\n☐Pre-commencement communications pursuant to Rule 14d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐Pre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Exchange Act:\n\n \n\n**Title of Each Class**\n**Trading Symbol**\n**Name of Each Exchange on Which Registered**\n\nCommon Shares, par value CHF 0.08 per share\nADCT\nNew York Stock Exchange\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of\n1934 (17 C.F.R. §240.12b-2). Emerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐"}